Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1896 | 5944 | 32.1 | 64% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
176 | 3 | DIABETES CARE//ENDOCRINOLOGY & METABOLISM//TYPE 2 DIABETES | 58057 |
1896 | 2 | METFORMIN//ACARBOSE//REPAGLINIDE | 5944 |
6705 | 1 | GLIMEPIRIDE//JTT 608//SECONDARY FAILURE | 1453 |
8357 | 1 | ACARBOSE//ALPHA GLUCOSIDASE INHIBITOR//MIGLITOL | 1262 |
8850 | 1 | METFORMIN//LACTIC ACIDOSIS//BIGUANIDES | 1211 |
16225 | 1 | REPAGLINIDE//NATEGLINIDE//MITIGLINIDE | 666 |
16766 | 1 | METFORMIN HYDROCHLORIDE//GLIMEPIRIDE//GLICLAZIDE | 637 |
22786 | 1 | GLICLAZIDE//ARTIFICIAL CELL MICROENCAPSULATION//BIOTECHNOL DRUG DEV | 369 |
23415 | 1 | INSULIN OVERDOSE//BIOCHEMICAL HYPOGLYCEMIA//LETHAL HYPOGLYCAEMIA | 346 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | METFORMIN | authKW | 766423 | 13% | 20% | 749 |
2 | ACARBOSE | authKW | 426751 | 3% | 43% | 193 |
3 | REPAGLINIDE | authKW | 334207 | 2% | 52% | 125 |
4 | GLICLAZIDE | authKW | 325837 | 2% | 46% | 138 |
5 | ALPHA GLUCOSIDASE INHIBITOR | authKW | 323823 | 3% | 37% | 170 |
6 | GLIMEPIRIDE | authKW | 308768 | 2% | 44% | 137 |
7 | NATEGLINIDE | authKW | 294540 | 2% | 59% | 97 |
8 | MIGLITOL | authKW | 212772 | 1% | 70% | 59 |
9 | MITIGLINIDE | authKW | 167667 | 1% | 82% | 40 |
10 | ALPHA GLUCOSIDASE | authKW | 147511 | 3% | 17% | 171 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Endocrinology & Metabolism | 39658 | 32% | 0% | 1892 |
2 | Pharmacology & Pharmacy | 8982 | 24% | 0% | 1445 |
3 | Medicine, General & Internal | 3735 | 13% | 0% | 770 |
4 | Chemistry, Analytical | 1210 | 8% | 0% | 450 |
5 | Chemistry, Medicinal | 726 | 4% | 0% | 240 |
6 | Nutrition & Dietetics | 484 | 3% | 0% | 179 |
7 | Biochemical Research Methods | 471 | 4% | 0% | 234 |
8 | Medicine, Research & Experimental | 439 | 4% | 0% | 262 |
9 | Food Science & Technology | 371 | 4% | 0% | 240 |
10 | Integrative & Complementary Medicine | 216 | 1% | 0% | 52 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | BIOTECHNOL DRUG DEV | 38673 | 0% | 42% | 18 |
2 | PHARMBIOSCI PRECINCT | 20541 | 0% | 100% | 4 |
3 | BIOTECHNOL DRUG DEV BIOSCI PRECINCT | 15406 | 0% | 100% | 3 |
4 | HIGASHISONOGI TEA BRANCH | 15406 | 0% | 100% | 3 |
5 | BIOSCI PRECINCT | 13853 | 0% | 30% | 9 |
6 | FOOD BIOCHEMKITA KU | 13135 | 0% | 32% | 8 |
7 | BEZAFIBRATE INFARCT PREVENT COORDINATING | 11553 | 0% | 75% | 3 |
8 | NAZL INFORMAZ TOSSICOL | 11553 | 0% | 75% | 3 |
9 | PHARMACEUT REGULATORY AFFAIRS QUAL ASSURANCE DE | 11553 | 0% | 75% | 3 |
10 | BELGYOGYASZAT DIABETOL 2 | 10271 | 0% | 100% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | DIABETES & METABOLISM | 48393 | 3% | 6% | 164 |
2 | DIABETES CARE | 29232 | 4% | 2% | 256 |
3 | DIABETES RESEARCH AND CLINICAL PRACTICE | 24622 | 3% | 3% | 160 |
4 | DIABETES OBESITY & METABOLISM | 20464 | 2% | 4% | 94 |
5 | DIABETIC MEDICINE | 15304 | 2% | 2% | 131 |
6 | METABOLISM-CLINICAL AND EXPERIMENTAL | 12497 | 2% | 2% | 148 |
7 | HORMONE AND METABOLIC RESEARCH | 7185 | 2% | 2% | 95 |
8 | ACTA DIABETOLOGICA LATINA | 6708 | 0% | 5% | 24 |
9 | DIABETOLOGIA | 4541 | 1% | 1% | 87 |
10 | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 3959 | 1% | 1% | 75 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | METFORMIN | 766423 | 13% | 20% | 749 | Search METFORMIN | Search METFORMIN |
2 | ACARBOSE | 426751 | 3% | 43% | 193 | Search ACARBOSE | Search ACARBOSE |
3 | REPAGLINIDE | 334207 | 2% | 52% | 125 | Search REPAGLINIDE | Search REPAGLINIDE |
4 | GLICLAZIDE | 325837 | 2% | 46% | 138 | Search GLICLAZIDE | Search GLICLAZIDE |
5 | ALPHA GLUCOSIDASE INHIBITOR | 323823 | 3% | 37% | 170 | Search ALPHA+GLUCOSIDASE+INHIBITOR | Search ALPHA+GLUCOSIDASE+INHIBITOR |
6 | GLIMEPIRIDE | 308768 | 2% | 44% | 137 | Search GLIMEPIRIDE | Search GLIMEPIRIDE |
7 | NATEGLINIDE | 294540 | 2% | 59% | 97 | Search NATEGLINIDE | Search NATEGLINIDE |
8 | MIGLITOL | 212772 | 1% | 70% | 59 | Search MIGLITOL | Search MIGLITOL |
9 | MITIGLINIDE | 167667 | 1% | 82% | 40 | Search MITIGLINIDE | Search MITIGLINIDE |
10 | ALPHA GLUCOSIDASE | 147511 | 3% | 17% | 171 | Search ALPHA+GLUCOSIDASE | Search ALPHA+GLUCOSIDASE |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | CUSI, K , DEFRONZO, RA , (1998) METFORMIN: A REVIEW OF ITS METABOLIC EFFECTS.DIABETES REVIEWS. VOL. 6. ISSUE 2. P. 89 -131 | 218 | 69% | 180 |
2 | SALPETER, SR , GREYBER, E , PASTERNAK, GA , SALPETER, EE , (2010) RISK OF FATAL AND NONFATAL LACTIC ACIDOSIS WITH METFORMIN USE IN TYPE 2 DIABETES MELLITUS.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 4. P. - | 199 | 52% | 14 |
3 | RENDELL, M , (2004) THE ROLE OF SULPHONYLUREAS IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS.DRUGS. VOL. 64. ISSUE 12. P. 1339-1358 | 160 | 60% | 145 |
4 | INZUCCHI, SE , LIPSKA, KJ , MAYO, H , BAILEY, CJ , MCGUIRE, DK , (2014) METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE A SYSTEMATIC REVIEW.JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. VOL. 312. ISSUE 24. P. 2668 -2675 | 60 | 91% | 81 |
5 | DEFRONZO, R , FLEMING, GA , CHEN, K , BICSAK, TA , (2016) METFORMIN-ASSOCIATED LACTIC ACIDOSIS: CURRENT PERSPECTIVES ON CAUSES AND RISK.METABOLISM-CLINICAL AND EXPERIMENTAL. VOL. 65. ISSUE 2. P. 20 -29 | 60 | 81% | 11 |
6 | SALPETER, SR , GREYBER, E , PASTERNAK, GA , SALPETER, EE , (2003) RISK OF FATAL AND NONFATAL LACTIC ACIDOSIS WITH METFORMIN USE IN TYPE 2 DIABETES MELLITUS - SYSTEMATIC REVIEW AND META-ANALYSIS.ARCHIVES OF INTERNAL MEDICINE. VOL. 163. ISSUE 21. P. 2594-2602 | 121 | 79% | 128 |
7 | SALPETER, S , GREYBER, E , PASTERNAK, G , SALPETER, E , (2003) RISK OF FATAL AND NONFATAL LACTIC ACIDOSIS WITH METFORMIN USE IN TYPE 2 DIABETES MELLITUS.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 3. P. - | 138 | 78% | 20 |
8 | CALELLO, DP , LIU, KD , WIEGAND, TJ , ROBERTS, DM , LAVERGNE, V , GOSSELIN, S , HOFFMAN, RS , NOLIN, TD , GHANNOUM, M , (2015) EXTRACORPOREAL TREATMENT FOR METFORMIN POISONING: SYSTEMATIC REVIEW AND RECOMMENDATIONS FROM THE EXTRACORPOREAL TREATMENTS IN POISONING WORKGROUP.CRITICAL CARE MEDICINE. VOL. 43. ISSUE 8. P. 1716 -1730 | 86 | 80% | 6 |
9 | HOWLETT, HCS , BAILEY, CJ , (1999) A RISK-BENEFIT ASSESSMENT OF METFORMIN IN TYPE 2 DIABETES MELLITUS.DRUG SAFETY. VOL. 20. ISSUE 6. P. 489 -503 | 103 | 76% | 108 |
10 | KAJBAF, F , DE BROE, ME , LALAU, JD , (2016) THERAPEUTIC CONCENTRATIONS OF METFORMIN: A SYSTEMATIC REVIEW.CLINICAL PHARMACOKINETICS. VOL. 55. ISSUE 4. P. 439 -459 | 83 | 69% | 0 |
Classes with closest relation at Level 2 |